# US 2016/0355511 A1 · Novel 1-substituted indazole derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355511 A1
- Document ID: US20160355511A1
- Status: Published application
- Kind: A1
- Application number: 15/060,902
- Filed: 2016-03-04
- Published: 2016-12-08
- Earliest claimed: 2012-04-10
- Assignees: Sumitomo Dainippon Pharma Co., Ltd.
- Applicants: Sumitomo Dainippon Pharma Co., Ltd.
- Inventors: Shinya Usui; Hiroki Yamaguchi; Yoko Nakai
- Web page: https://patentgrep.com/patent/US20160355511A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): wherein A is CR1E or a nitrogen atom, X—Y—Z is N—CO—NR3AR3B and the like, R1A to R1E are each independently a hydrogen atom and the like, R2A to R2D are each independently a hydrogen atom and the like, R3A and R3B are each independently an optionally-substituted C3-10 cycloalkyl and the like, and n is 1 or 2 or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of α7 nicotinic acetylcholine receptor (α7 nAChR).

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof
wherein
A is CR1E or a nitrogen atom,
X—Y—Z is N—CO—NR3AR3B, N—CO—R4, CR2E—CO—NR3AR3B, CR2E—NR5—COR4 or CR2E—NR5—CONR3AR3B,
R1A is a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, a C3-6 cycloalkyl, —NR6R7, —CONR6R7 and —NR6COR7; a C3-10 cycloalkyl or a 4- to 10-membered saturated heterocycle (wherein the cycloalkyl and the saturated heterocycle may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR6R7); a C1-6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, —NR6R7, —CONR6R7 and —NR6COR7; a hydrogen atom; a halogen; —NR6R7; a cyano group; —CONR6R7; —NR6COR7; or —SO2R6, provided that both R6 and R7 are not a hydrogen atom,
R1B to R1E are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, a C3-6 cycloalkyl, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′; a C3-10 cycloalkyl or a 4- to 10-membered saturated heterocycle (wherein the cycloalkyl and the saturated heterocycle may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′); a C1-6 alkoxy or a C3-10 cycloalkoxy (wherein the alkoxy and the cycloalkoxy may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, —CONR6′R7′ and —NR6′COR7′); a hydrogen atom; a hydroxy group; a halogen; an aryl or a heteroaryl (wherein the aryl and the heteroaryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a halogen, a hydroxy group, a C1-6 alkyl optionally substituted with 1 to 5 fluorine atoms, a C1-6 alkoxy, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′); —NR6′R7′; a cyano group; —CONR6′R7′; —NR6′COR7′; or —SO2R6′, provided that both R6′ and R7′ are not a hydrogen atom,
R2A to R2E are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a halogen, a hydroxy group, a C1-6 alkoxy and —NR8R9; a hydrogen atom; a halogen; a hydroxy group; or a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms, or when two of R2A to R2E are a C1-6 alkyl, they may be taken together to form a 4- to 10-membered saturated carbocyclic ring (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR8R9),
R3A, R3B and R4 are each independently a C1-10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of phenyl, a monocyclic heteroaryl, a 4- to 10-membered saturated heterocycle, a C3-10 cycloalkyl, a fluorine atom, a hydroxy group, a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms, and —NR10R11; a C3-10 cycloalkyl; a 4- to 10-membered saturated heterocycle; phenyl; a monocyclic heteroaryl; or a hydrogen atom, wherein the cycloalkyl, the saturated heterocycle, the phenyl and the monocyclic heteroaryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of an aryl (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkoxy and —NR10R11), a halogen, a hydroxy group, a C1-6 alkyl (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkoxy and —NR10R11), a C1-6 alkoxy (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a C3-6 cycloalkyl, a C3-6 cycloalkyl-C1-6 alkyl, a C1-6 alkoxy and a fluorine atom), a C1-6 alkylcarbonyl and —NR10R11, provided that (1) R3A and R3B may be taken together to form a 4- to 10-membered saturated heterocycle (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR10R11), (2) only one of R3A and R3B can be a hydrogen atom, and (3) R4 is not a hydrogen atom,
R5 to R11, R6′ and R7′ are the same or different (each symbol is also the same or different when each symbol exists plurally) and are a hydrogen atom or a C1-6 alkyl optionally substituted with 1 to 5 fluorine atoms, provided that in each combination of R6-R7, R6′-R7′, R8-R9, and R10-R11, (1) when one is a hydrogen atom, the other one is not a hydrogen atom, and (2) each combination may be taken together to form a 4- to 10-membered saturated heterocycle (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR6R7), and
n is 1 or 2.

### Claim 2 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein X—Y—Z is N—CO—NR3AR3B, N—CO—R4 or CR2E—NR5—COR4.

### Claim 3 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein n is 1.

### Claim 4 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein either R3A or R3B is a hydrogen atom.

### Claim 5 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R2A to R2E are each independently a C1-6 alkyl optionally substituted with 1 to 5 fluorine atoms; a C1-6 alkoxy; a hydrogen atom; or a fluorine atom.

### Claim 6 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R3A, R3B and R4 are each independently a C1-10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a 4- to 10-membered saturated heterocycle, a C3-10 cycloalkyl, a fluorine atom, a hydroxy group, a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms and —NR10R11; a C3-10 cycloalkyl; a 4- to 10-membered saturated heterocycle; a nitrogen-containing monocyclic heteroaryl; or a hydrogen atom, wherein the cycloalkyl, the saturated heterocycle and the nitrogen-containing monocyclic heteroaryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkoxy and —NR10R11), a C1-6 alkoxy optionally substituted with a C3-6 cycloalkyl or 1 to 5 fluorine atoms and —NR10R11, provided that (1) R3A and R3B may be taken together to form a 4- to 10-membered nitrogen-containing saturated heterocycle (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR10R11), (2) only one of R3A and R3B can be a hydrogen atom, and (3) R4 is not a hydrogen atom.

### Claim 7 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R1A to R1E are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C3-6 cycloalkyl, a hydroxy group and a C1-6 alkoxy; a C3-8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl and a C1-6 alkoxy; a C1-6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group and a C1-6 alkoxy; a hydrogen atom; a halogen; or a 4- to 10-membered saturated heterocycle optionally substituted with a C1-6 alkyl.

### Claim 8 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein X—Y—Z is N—CO—NR3AR3B or CR2E—NR5—COR4.

### Claim 9 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein A is CR1E.

### Claim 10 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R3A, R3B and R4 are each independently a C1-10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom and a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms; a C3-10 cycloalkyl; a 4- to 10-membered saturated heterocycle; or a hydrogen atom, wherein the cycloalkyl and the saturated heterocycle may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkyl (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom and a C1-6 alkoxy) and a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms, provided that (1) only one of R3A and R3B can be a hydrogen atom, and (2) R4 is not a hydrogen atom.

### Claim 11 (depends on 7)

The compound of claim 7 or a pharmaceutically acceptable salt thereof wherein R1A to R1E are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom and a C1-6 alkoxy; a C3-8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkyl and a C1-6 alkoxy; a C1-6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom and a C1-6 alkoxy; a hydrogen atom; or a halogen.

### Claim 12 (depends on 8)

The compound of claim 8 or a pharmaceutically acceptable salt thereof wherein X—Y—Z is N—CO—NR3AR3B.

### Claim 13 (depends on 1)

The compound of claim 1 selected from the following compounds or a pharmaceutically acceptable salt thereof:
N-(cis-4-(5-ethyl-1H-indazol-1-yl)cyclohexyl)-4,4-difluorocyclohexanecarboxamide,
1-(4,4-difluorocyclohexyl)-3-(cis-4-(5-ethyl-1H-indazol-1-yl)cyclohexyl)urea, and
cis-N-(4,4-difluorocyclohexyl)-4-(5-ethyl-1H-indazol-1-yl)cyclohexanecarboxamide.

### Claim 14

(canceled)

### Claim 15

A compound of Formula (I′):
or a pharmaceutically acceptable salt thereof
wherein
A is CR1E;
X—Y—Z is N—CO—NR3AR3B;
R1A to R1E are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom and a C1-6 alkoxy; a C3-8 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkyl and a C1-6 alkoxy; a C1-6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom and a C1-6 alkoxy; a hydrogen atom; or a halogen;
R2A to R2E are each independently a C1-6 alkyl optionally substituted with 1 to 5 fluorine atoms; a C1-6 alkoxy; a hydrogen atom; or a fluorine atom;
R3A and R3B are each independently a C1-10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom and a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms; a C3-10 cycloalkyl; a 4- to 10-membered saturated heterocycle; or a hydrogen atom, wherein the cycloalkyl and the saturated heterocycle may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkyl (which may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom and a C1-6 alkoxy) and a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms, provided that either R3A or R3B is a hydrogen atom; and
n is 1.

### Claim 16 (depends on 1, 15)

A pharmaceutical composition comprising the compound of either claim 1 or 15 or a pharmaceutically acceptable salt thereof.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1, 15)

A method for treating or preventing a nervous system disease, psychiatric disease or inflammatory disease which comprises administering a therapeutically effective amount of the compound of either claim 1 or 15 or a pharmaceutically acceptable salt thereof to a patient in need thereof.

### Claim 20 (depends on 1, 15)

A combination drug comprising the compound of either claim 1 or 15 or a pharmaceutically acceptable salt thereof, and at least one drug selected from drugs classified as atypical antipsychotic drugs.

### Claim 21 (depends on 1, 15)

A method for treating a disease due to an abnormality of the intracellular signaling mediated by acetylcholine which comprises administering a therapeutically effective amount of the compound of either claim 1 or 15 or a pharmaceutically acceptable salt thereof to a patient in need thereof.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

A method for treating or preventing a nervous system disease, psychiatric disease or inflammatory disease which comprises administering a therapeutically effective amount of the compound of Formula (I″):
or a pharmaceutically acceptable salt thereof
wherein
A is CR1E,
X—Y—Z is N—CO—NR3AR3B or N—CO—R4,
R1A is a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, a C3-6 cycloalkyl, —NR6R7, —CONR6R7 and —NR6COR7; a C3-10 cycloalkyl or a 4- to 10-membered saturated heterocycle, wherein the cycloalkyl and the saturated heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR6R7; a C1-6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, —NR6R7, —CONR6R7 and —NR6COR7; a hydrogen atom; a halogen; —NR6R7; a cyano group; —CONR6R7; —NR6COR7; or —SO2R6, provided that both R6 and R7 are not a hydrogen atom,
R1B to R1E are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, a C3-6 cycloalkyl, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′; a C3-10 cycloalkyl or a 4- to 10-membered saturated heterocycle, wherein the cycloalkyl and the saturated heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′; a C1-6 alkoxy or a C3-10 cycloalkoxy, wherein the alkoxy and the cycloalkoxy are optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, —CONR6′R7′ and —NR6′COR7′; a hydrogen atom; a hydroxy group; a halogen; an aryl or a heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with 1 to 5 substituents independently selected from the group consisting of a halogen, a hydroxy group, a C1-6 alkyl optionally substituted with 1 to 5 fluorine atoms, a C1-6 alkoxy, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′; —NR6′R7′; a cyano group; —CONR6′R7′; —NR6′COR7′; or —SO2R6′, provided that both R6′ and R7′ are not a hydrogen atom,
R2A to R2D are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a halogen, a hydroxy group, a C1-6 alkoxy and —NR8R9; a hydrogen atom; a halogen; a hydroxy group; or a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms, or when two of R2A to R2D are a C1-6 alkyl, they may be taken together to form a 4- to 10-membered saturated carbocyclic ring optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR8R9,
R3A, R3B and R4 are each independently a C1-10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of phenyl, a monocyclic heteroaryl, a 4- to 10-membered saturated heterocycle, a C3-10 cycloalkyl, a fluorine atom, a hydroxy group, a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms, and —NR10R11; a C3-10 cycloalkyl; a 4- to 10-membered saturated heterocycle; phenyl; a monocyclic heteroaryl; or a hydrogen atom, wherein the cycloalkyl, the saturated heterocycle, the phenyl and the monocyclic heteroaryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of an aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkoxy and —NR10R11, a halogen, a hydroxy group, a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkoxy and —NR10R11, a C1-6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of a C3-6 cycloalkyl, a C3-6 cycloalkyl-C1-6 alkyl, a C1-6 alkoxy and a fluorine atom, a C1-6 alkylcarbonyl, and —NR10R11, provided that (1) R3A and R3B may be taken together to form a 4- to 10-membered saturated heterocycle optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR10R11, (2) only one of R3A and R3B can be a hydrogen atom, and (3) R4 is not a hydrogen atom,
R6 to R11, R6′ and R7′ are the same or different and are a hydrogen atom or a C1-6 alkyl optionally substituted with 1 to 5 fluorine atoms, provided that in each combination of R6-R7, R6′-R7′, R8-R9, and R10-R11, (1) when one is a hydrogen atom, the other one is not a hydrogen atom, and (2) each combination may be taken together to form a 4- to 10-membered saturated heterocycle optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR6R7, and
n is 1.

### Claim 25 (depends on 24)

The method of claim 24 wherein the nervous system disease, the psychiatric disease or the inflammatory disease is dementia, schizophrenia, Alzheimer's disease, Down's syndrome, attention deficit disorder or cerebral angiopathy.

### Claim 26

A method for treating a disease due to an abnormality of the intracellular signaling mediated by acetylcholine which comprises administering a therapeutically effective amount of the compound of Formula (I″):
or a pharmaceutically acceptable salt thereof
wherein
A is CR1E,
X—Y—Z is N—CO—NR3AR3B or N—CO—R4,
R1A is a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, a C3-6 cycloalkyl, —NR6R7, —CONR6R7 and —NR6COR7; a C3-10 cycloalkyl or a 4- to 10-membered saturated heterocycle, wherein the cycloalkyl and the saturated heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR6R7; a C1-6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, —NR6R7, —CONR6R7 and —NR6COR7; a hydrogen atom; a halogen; —NR6R7; a cyano group; —CONR6R7; —NR6COR7; or —SO2R6, provided that both R6 and R7 are not a hydrogen atom,
R1B to R1E are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, a C3-6 cycloalkyl, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′; a C3-10 cycloalkyl or a 4- to 10-membered saturated heterocycle, wherein the cycloalkyl and the saturated heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′; a C1-6 alkoxy or a C3-10 cycloalkoxy, wherein the alkoxy and the cycloalkoxy are optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkoxy, —CONR6′R7′ and —NR6′COR7′; a hydrogen atom; a hydroxy group; a halogen; an aryl or a heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with 1 to 5 substituents independently selected from the group consisting of a halogen, a hydroxy group, a C1-6 alkyl optionally substituted with 1 to 5 fluorine atoms, a C1-6 alkoxy, —NR6′R7′, —CONR6′R7′ and —NR6′COR7′; —NR6′R7′; a cyano group; —CONR6′R7′; —NR6′COR7′; or —SO2R6′, provided that both R6′ and R7′ are not a hydrogen atom,
R2A to R2D are each independently a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a halogen, a hydroxy group, a C1-6 alkoxy and —NR8R9; a hydrogen atom; a halogen; a hydroxy group; or a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms, or when two of R2A to R2D are a C1-6 alkyl, they may be taken together to form a 4- to 10-membered saturated carbocyclic ring optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR8R9,
R3A, R3B and R4 are each independently a C1-10 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of phenyl, a monocyclic heteroaryl, a 4- to 10-membered saturated heterocycle, a C3-10 cycloalkyl, a fluorine atom, a hydroxy group, a C1-6 alkoxy optionally substituted with 1 to 5 fluorine atoms, and —NR10R11; a C3-10 cycloalkyl; a 4- to 10-membered saturated heterocycle; phenyl; a monocyclic heteroaryl; or a hydrogen atom, wherein the cycloalkyl, the saturated heterocycle, the phenyl and the monocyclic heteroaryl may be optionally substituted with 1 to 5 substituents independently selected from the group consisting of an aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkoxy and —NR10R11, a halogen, a hydroxy group, a C1-6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a C1-6 alkoxy and —NR10R11, a C1-6 alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of a C3-6 cycloalkyl, a C3-6 cycloalkyl-C1-6 alkyl, a C1-6 alkoxy and a fluorine atom, a C1-6 alkylcarbonyl, and —NR10R11, provided that (1) R3A and R3B may be taken together to form a 4- to 10-membered saturated heterocycle optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR10R11, (2) only one of R3A and R3B can be a hydrogen atom, and (3) R4 is not a hydrogen atom,
R6 to R11, R6′ and R7′ are the same or different and are a hydrogen atom or a C1-6 alkyl optionally substituted with 1 to 5 fluorine atoms, provided that in each combination of R6-R7, R6′-R7′, R8-R9, and R10-R11, (1) when one is a hydrogen atom, the other one is not a hydrogen atom, and (2) each combination may be taken together to form a 4- to 10-membered saturated heterocycle optionally substituted with 1 to 5 substituents independently selected from the group consisting of a fluorine atom, a hydroxy group, a C1-6 alkyl, a C1-6 alkoxy and —NR6R7, and
n is 1.

### Claim 27 (depends on 19)

The method of claim 19 wherein the nervous system disease, the psychiatric disease or the inflammatory disease is dementia, schizophrenia, CIAS (cognitive impairment associated with schizophrenia), Alzheimer's disease, Down's syndrome, attention deficit disorder or cerebral angiopathy.
